Immune-related adverse events
| Number of irAEs | |
| One irAE | 97 (75%) |
| Multiple irAEs | 32 (25%) |
| ICI monotherapy | 11 |
| ICI and non-ICI | 10 |
| ICI and ICI | 11 |
| Type of irAEs | |
| Colitis/enteritis | 55 (32%) |
| Pneumonitis | 51 (30) |
| Hepatitis | 23 (14%) |
| Thyroiditis | 8 (5%) |
| Myocarditis | 5 (3%) |
| Dermatitis | 5 (3%) |
| Myositis | 4 (2%) |
| Arthritis | 4 (2%) |
| Hypophysitis | 4 (2%) |
| Adrenal insufficiency | 3 (2%) |
| Nephritis | 2 (1%) |
| Pancreatitis | 2 (1%) |
| Flare of underlying autoimmune disease | 2 (1%) |
| Others | 2 (1%) |
| CTCAE grade of irAEs | |
| Grade 3 (severe) | 110 (85%) |
| Grade 4 (life-threatening) | 14 (11%) |
| Grade 5 (fatal) | 5 (4%) |
| Hospital course | |
| Length of hospital stay (mean) | 11 days |
| Patients admitted to ICU | 11 (8%) |
| Length of ICU stay (mean) | 7 days |
| Management of irAEs | |
| Methylprednisolone | 102 (80%) |
| Prednisone | 21 (17%) |
| Dexamethasone | 2 (1.5%) |
| Hydrocortisone | 2 (1.5%) |
| Steroids-refractory irAEs | 12 (9%) |
| Infliximab | 6 |
| IVIG | 2 |
| Infliximab and IVIG | 1 |
| Mycophenolate mofetil | 2 |
| Vedolizumab | 1 |
| Dose of steroids | |
| <1 mg/kg/day | 10 (8%) |
| =1 mg/kg/day | 79 (62%) |
| >1 mg/kg/day | 38 (30%) |
| The irAEs-related admissions | |
| Total number of admissions | 194 |
| ITOX service | 140 (72%) |
| Other services | 54 (28%) |
| Readmission rate | 26.00% |
CTCAE, common Terminology Criteria for Adverse Events; ICI, immune checkpoint inhibitor; ICU, intensive care unit; irAEs, immune-related adverse events; ITOX, immune toxicity; IVIG, intravenous immunoglobulin.